p.134 抽出テキスト

335. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol 2016;67:353–61. https://doi.org/ 10.1016/j.jacc.2015.10.077 336. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664 337. Westin GG, Armstrong EJ, Bang H, Yeo K-K, Anderson D, Dawson DL, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014;63:682–90. https://doi.org/10.1016/j.jacc.2013.09.073 338. Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, et al. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. Vasa 2021;50:401–11. https://doi.org/10.1024/0301-1526/a000969 339. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009;38:463–74. https://doi.org/10.1016/j.ejvs.2009.06.002 340. Flint AC, Conell C, Ren X, Kamel H, Chan SL, Rao VA, et al. Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation. Stroke 2017;48:1788–94. https://doi.org/10.1161/strokeaha.117.017343 341. Merwick Á, Albers GW, Arsava EM, Ay H, Calvet D, Coutts SB, et al. Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment. Stroke 2013;44:2814–20. https://doi.org/10.1161/strokeaha.113.001576 342. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453–63. https://doi.org/10.1016/s1474-4422(09)70058-4 343. Amarenco P, Bogousslavsky J, Callahan A, III, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–59. https://doi.org/10.1056/NEJMoa061894 344. Hackam DG, Wu F, Li P, Austin PC, Tobe SW, Mamdani MM, et al. Statins and renovascular disease in the elderly: a population-based cohort study. Eur Heart J 2011;32: 598–610. https://doi.org/10.1093/eurheartj/ehq452 345. Peng M, Dong H, Jiang X, Che W, Zou Y, Zhang Y, et al. A randomized unblinded trial to compare effects of intensive versus conventional lipid-lowering therapy in patients undergoing renal artery stenting. J Cardiol 2019;74:443–50. https://doi.org/10.1016/j. jjcc.2019.04.010 346. Vashist A, Heller EN, Brown EJ, Jr, Alhaddad IA. Renal artery stenosis: a cardiovascular perspective. Am Heart J 2002;143:559–64. https://doi.org/10.1067/mhj.2002.120769 347. Pan Z, Cui H, Wu N, Zhang H. Effect of statin therapy on abdominal aortic aneurysm growth rate and mortality: a systematic review and meta-analysis. Ann Vasc Surg 2020; 67:503–10. https://doi.org/10.1016/j.avsg.2020.03.036 348. Salata K, Syed M, Hussain MA, de Mestral C, Greco E, Mamdani M, et al. Statins reduce abdominal aortic aneurysm growth, rupture, and perioperative mortality: a systematic review and meta-analysis. J Am Heart Assoc 2018;7:e008657. https://doi.org/10.1161/ jaha.118.008657 349. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies. Eur J Vasc Endovasc Surg 2012;44:287–92. https://doi.org/10.1016/ j.ejvs.2012.06.021 350. Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic aneurysms. Am J Cardiol 2013;112:1240–5. https://doi.org/10.1016/j.amjcard.2013.05. 081 351. Jovin IS, Duggal M, Ebisu K, Paek H, Oprea AD, Tranquilli M, et al. Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug. Am J Cardiol 2012;109:1050–4. https://doi.org/10.1016/j. amjcard.2011.11.038 352. Skovbo Kristensen JS, Krasniqi L, Obel LM, Kavaliunaite E, Liisberg M, Lindholt JS. Exploring drug repurposing for treatment of abdominal aortic aneurysms: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2024;67:570–82. https://doi.org/10. 1016/j.ejvs.2023.11.037 353. Rahman MN, Khan JA, Mazari FA, Mockford K, McCollum PT, Chetter IC. A randomized placebo controlled trial of the effect of preoperative statin use on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and peak wall stress in patients undergoing elective open repair of abdominal aortic aneurysm. Ann Vasc Surg 2011;25:32–8. https://doi.org/10.1016/j.avsg.2010.06.006 354. Periard D, Guessous I, Mazzolai L, Haesler E, Monney P, Hayoz D. Reduction of small infrarenal abdominal aortic aneurysm expansion rate by statins. Vasa 2012;41:35–42. https://doi.org/10.1024/0301-1526/a000161 355. Angeloni E, Vitaterna A, Pirelli M, Refice S. Effects of statin therapy on ascending aorta aneurysms growth: a propensity-matched analysis. Int J Cardiol 2015;191:52–5. https:// doi.org/10.1016/j.ijcard.2015.05.001 356. Rowbotham SE, Krishna SM, Moran CS, Golledge J. Fenofibrate and telmisartan in the management of abdominal aortic aneurysm. Curr Drug Targets 2018;19:1241–6. https:// doi.org/10.2174/1389450119666171227224655 357. Pinchbeck JL, Moxon JV, Rowbotham SE, Bourke M, Lazzaroni S, Morton SK, et al. Randomized placebo-controlled trial assessing the effect of 24-week fenofibrate therapy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME-2 trial. J Am Heart Assoc 2018;7:e009866. https://doi.org/10.1161/JAHA.118.009866 358. Lamb YN. Inclisiran: first approval. Drugs 2021;81:389–95. https://doi.org/10.1007/ s40265-021-01473-6 359. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380: 1022–32. https://doi.org/10.1056/NEJMoa1803917 360. Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 2018; 277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002 361. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023; 388:1353–64. https://doi.org/10.1056/NEJMoa2215024 362. Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, et al. Elevated LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 2023;81:136–52. https:// doi.org/10.1016/j.jacc.2022.10.019 363. Gao JW, Hao QY, Gao M, Zhang K, Li X-Z, Wang J-F, et al. Triglyceride-glucose index in the development of peripheral artery disease: findings from the Atherosclerosis Risk in Communities (ARIC) study. Cardiovasc Diabetol 2021;20:126. https://doi.org/10. 1186/s12933-021-01319-1 364. Britton KA, Mukamal KJ, Ix JH, Siscovick DS, Newman AB, de Boer IH, et al. Insulin resistance and incident peripheral artery disease in the cardiovascular health study. Vasc Med 2012;17:85–93. https://doi.org/10.1177/1358863X11436195 365. Pande RL, Perlstein TS, Beckman JA, Creager MA. Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004. Circulation 2008;118:33–41. https://doi.org/10. 1161/CIRCULATIONAHA.107.721878 366. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015;10:CD009580. https://doi. org/10.1002/14651858.CD009580.pub2 367. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325:1139. https://doi.org/10.1136/ bmj.325.7373.1139 368. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792 369. Bhatt DS, Steg PG, Miller M, Brinton E, Jacobson T, Tardif J-C, et al. Abstract 10627: benefits of icosapent ethyl in patients with prior peripheral artery disease: REDUCE-IT PAD. Circulation 2021;144:A10627. https://doi.org/10.1161/circ.144. suppl_1.10627 370. Kobayashi Y, Fujikawa T, Haruna A, Kawano R, Ozawa M, Haze T, et al. Omega-3 fatty acids reduce remnant-like lipoprotein cholesterol and improve the ankle-brachial index of hemodialysis patients with dyslipidemia: a pilot study. Medicina (Kaunas) 2024;60:75. https://doi.org/10.3390/medicina60010075 371. Dopheide JF, Veit J, Ramadani H, Adam L, Papac L, Vonbank A, et al. Adherence to statin therapy favours survival of patients with symptomatic peripheral artery disease. Eur Heart J Cardiovasc Pharmacother 2021;7:263–70. https://doi.org/10.1093/ehjcvp/ pvz081 372. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 2018;137:338–50. https://doi.org/10.1161/circulationaha.117.032235 373. Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, et al. Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial. Eur Heart J 2021;42:4821–9. https://doi.org/10.1093/eurheartj/ ehab604 374. Marx N, Federici M, Schutt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192 375. Lazzarini PA, Cramb SM, Golledge J, Morton JI, Magliano DJ, Van Netten JJ. Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century. Diabetologia 2023;66:267–87. https://doi.org/10.1007/s00125-022-05845-9 376. Armstrong PA. Visceral duplex scanning: evaluation before and after artery intervention for chronic mesenteric ischemia. Perspect Vasc Surg Endovasc Ther 2007;19: 386–92; discussion 393–384. https://doi.org/10.1177/1531003507311802 377. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116: 1509–26. https://doi.org/10.1161/CIRCRESAHA.116.303849 378. McGurnaghan SJ, McKeigue PM, Read SH, Franzen S, Svensson A-M, Colombo M, et al. Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia 2021;64:2001–11. https://doi.org/10.1007/s00125-021-05478-4

ESC Guidelines                                                                                                                                                                                          3671

Downloaded from academic.oup.com/eurheartj/article/45/36/3538/7738955 by guest on 07 October 2026